50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How to profit from the coming boom in gold (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How to profit from the coming boom in gold (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How to profit from the coming boom in gold (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How to profit from the coming boom in gold (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
NASDAQ:CARA

Cara Therapeutics - CARA Stock Forecast, Price & News

$8.48
-0.32 (-3.64%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.36
$8.73
50-Day Range
$8.24
$12.56
52-Week Range
$7.40
$18.93
Volume
327,661 shs
Average Volume
338,546 shs
Market Capitalization
$455.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00

Cara Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
218.4% Upside
$27.00 Price Target
Short Interest
Bearish
17.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.39
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$143,604 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.34) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

558th out of 1,080 stocks

Pharmaceutical Preparations Industry

256th out of 535 stocks

CARA stock logo

About Cara Therapeutics (NASDAQ:CARA) Stock

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Stock News Headlines

Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Cara Therapeutics Inc - Stock Chart
Calls A Much Safer Way To Buy Cara Therapeutics
Cara Therapeutics Q1 2022 Earnings Preview
See More Headlines
Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Company Calendar

Last Earnings
8/08/2022
Today
9/24/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CARA
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+218.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-88,440,000.00
Net Margins
-135.72%
Pretax Margin
-135.72%

Debt

Sales & Book Value

Annual Sales
$23.03 million
Book Value
$4.25 per share

Miscellaneous

Free Float
52,007,000
Market Cap
$455.63 million
Optionable
Optionable
Beta
0.94

Key Executives

  • Mr. Christopher A. PosnerMr. Christopher A. Posner (Age 52)
    Pres, CEO & Director
    Comp: $431.9k
  • Dr. Derek T. Chalmers D.Sc. (Age 58)
    Ph.D., Co-Founder & Sr. Advisor
    Comp: $580.93k
  • Dr. Frédérique Menzaghi (Age 56)
    Chief Scientific Officer and Sr. VP of R&D
    Comp: $826.94k
  • Mr. Scott M. TerrillionMr. Scott M. Terrillion (Age 59)
    Chief Compliance Officer, Gen. Counsel & Corp. Sec.
    Comp: $689.63k
  • Dr. Joana GoncalvesDr. Joana Goncalves (Age 48)
    Chief Medical Officer
    Comp: $826.77k
  • Mr. Richard Makara (Age 52)
    VP, Head of Accounting, Controller, Principal Financial & Accounting Officer
  • Dr. Iris Francesconi Ph.D.
    Chief Strategy Officer & Head of Investor Relations
  • Mr. Eric Vandal
    Sr. VP of Commercial
  • Ms. Beth Weinberg
    Sr. VP of Regulatory Affairs & QA













CARA Stock - Frequently Asked Questions

Should I buy or sell Cara Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CARA shares.
View CARA analyst ratings
or view top-rated stocks.

What is Cara Therapeutics' stock price forecast for 2022?

3 analysts have issued twelve-month price targets for Cara Therapeutics' stock. Their CARA share price forecasts range from $20.00 to $30.00. On average, they predict the company's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 218.4% from the stock's current price.
View analysts price targets for CARA
or view top-rated stocks among Wall Street analysts.

How have CARA shares performed in 2022?

Cara Therapeutics' stock was trading at $12.18 at the start of the year. Since then, CARA stock has decreased by 30.4% and is now trading at $8.48.
View the best growth stocks for 2022 here
.

When is Cara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our CARA earnings forecast
.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) posted its earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.20. The biopharmaceutical company earned $23 million during the quarter, compared to analysts' expectations of $21.28 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 31.47% and a negative net margin of 135.72%.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (4.93%), State Street Corp (3.64%), Chescapmanager LLC (2.16%), Millennium Management LLC (1.45%), Pinnacle Associates Ltd. (1.39%) and Northern Trust Corp (1.24%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends
.

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $8.48.

How much money does Cara Therapeutics make?

Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $455.63 million and generates $23.03 million in revenue each year. The biopharmaceutical company earns $-88,440,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.

This page (NASDAQ:CARA) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.